AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04220645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opportunstic treatment
Description: opportunistically treating HCV infection immediately when hep C patients are hospitalized for acute care in psychiatric, addiction treatment or somatic wards
Study NCT04220645 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Referral at discharge
Study NCT02522091 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: functional brain MRI
Study NCT02450084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bandage
Description: After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
Study NCT02450084 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: IV-PCA containing Fentanyl
Description: All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl for 48 hours postoperatively.
Study NCT02450084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV-PCA containing Fentanyl
Description: All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl for 48 hours postoperatively.
Study NCT04901585 — intervention group
Intervention type: PROCEDURE
Intervention: Totally intracorporeal distal gastrectomy
Description: Minimally invasive distal gastrectomy with intracorporeal anastomosis and handsewn enterotomy closure
Study NCT04155814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose Injection
Description: USP 100 mg/5 mL (20 mg/mL), solution for IV injection, 100 mg unit dose strength
Study NCT04155814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venofer Injection
Description: (Iron Sucrose 20 mg/mL), solution for IV injection, 100 mg unit dose strength
Study NCT00359723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Study NCT01447121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tatsu/Tradewind Investigational BG Monitoring System
Description: Tradewind is a Bayer investigational meter that used an investigational sensor.
Study NCT02486250 — intervention group
Intervention type: OTHER
Intervention: Validation Study
Study NCT03042130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: standard of care
Study NCT03042130 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: standard of care
Study NCT03042130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Carboxymaltose
Description: Two IV doses
Study NCT01978626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App modules
Study NCT01978626 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional CBT-I
Study NCT06301139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Goat milk-based infant formula
Description: Infant formula based on goat milk for 4 weeks at volume depending on the infant
Study NCT06301139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cow's milk-based infant formula with probiotic drops
Description: Infant formula based on cow's milk with probiotic Lactobacillus reuteri drops for 4 weeks at volume depending on the infant
Study NCT02619721 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PINS SNS
Study NCT02619721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PINS SNS
Study NCT04804150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum suspension system active or inactive
Description: The device will be plugged in, or won't be plugged in, depending of the randomization. The patient and the investigator will not know whether the device is plugged in or not, and if the medical device is active or not
Study NCT05073198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education brochure
Description: In the content of the brochure about testicular cancer and CCTM prepared in line with the literature; It includes information such as the definition of testicular cancer, testicular cancer risk factors and symptoms, the importance of early diagnosis in testicular cancer, how CCTM is performed, and what to do in case of differences after the examination. Expert opinion was obtained from three faculty members (a professor from the Department of Urology, a professor in Public Health Nursing and a physician faculty member) regarding the content validity of the educational brochure created before the research.
Study NCT04621487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 14 days 1 gr bid
Study NCT04621487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 14 days 500 mg bid
Study NCT04621487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: 14 days 500 mg bid
Study NCT04621487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole 40mg
Description: 40 mg bid 14 days
Study NCT04621487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: according to antibiogram
Description: according to antibiogram
Study NCT01953900 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GD2 T cells
Description: On dose levels 1 and 2 each patient receives one injection of GD2 T cells followed by VZV vaccine injection 42 days later.~Dose Level 1: 1x10\^6 cells/m\^2~Dose Level 2: 1x10\^7 cells/m\^2~The next dose levels to be studied following Dose level 2 are Dose levels 7 and 8 where subjects will receive the VZV vaccine followed by a single infusion of iC9-GD2-CAR-VZV-CTLs within 48 hours after VZV vaccine:~Dose Level 7: 1 x 10\^7 cells/m2~Dose Level 8: 1 x 10\^8 cells/m\^2~Dose levels 9-11 will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine prior to administration of the T cells.~Dose Level 9: 1 x 10\^8 cells/m\^2~Dose Level 10: 5 x 10\^8 cells/m\^2~Dose Level 11: 1 x 10\^9 cells/m\^2~The previously planned dose levels 3-6 will not be studied.
Study NCT01953900 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VZV vaccine
Description: Subjects will receive a VZV vaccine with CTL infusion within 48 hours after the vaccine.
Study NCT01953900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m\^2/day followed by Fludarabine 30 mg/m\^2/day. Infusions should be given following hospital/pharmacy recommendations however at a minimum the cyclophosphamide should be infused over 1 hour and the fludarabine should be infused over 30 minutes. Mesna, IV hydration, and anti-emetics will be provided following local institutional guidelines. T cell infusion will take place the day after completion of chemotherapy. Zostavax will be administered two weeks after infusion of T cells.
Study NCT01953900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m\^2/day followed by Fludarabine 30 mg/m\^2/day. Infusions should be given following hospital/pharmacy recommendations however at a minimum the cyclophosphamide should be infused over 1 hour and the fludarabine should be infused over 30 minutes. Mesna, IV hydration, and anti-emetics will be provided following local institutional guidelines. T cell infusion will take place the day after completion of chemotherapy. Zostavax will be administered two weeks after infusion of T cells.
Study NCT04619355 — intervention group
Intervention type: DEVICE
Intervention: NIRS-IVUS
Description: Near-infrared spectroscopy-intravascular ultrasound can be implemented in parallel with intravascular ultrasound and provides important information for predicting prognosis by measuring the lipid component of atherosclerotic plaques.
Study NCT02654665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: Diet and exercise designed for 5-7% weight loss over 6 months
Study NCT02654665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: GLP-1 agonist
Study NCT00165542 — intervention group
Intervention type: OTHER
Intervention: A PROTEIN level
Study NCT01800318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NESAP
Description: Electrical stimulation will be administered via the Empi Select, a standard TENS unit. To produce analgesia, small electrodes will be placed in treatment groups on the baby's legs at specific acupuncture points: ZuSanLi (ST36), SanYinJiao (SP6), Shen Mai (Bl60), and Shui Quan (KI3)46. StimCare electrodes with a gel base will be applied to the skin ; the skin will not be punctured by these procedures. A low continuous current will be provided with minimal voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 2 minutes after the heel stick. The display will be hidden from view to prevent the rater from being able to observe whether the unit is on.
Study NCT01800318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 24% oral Sucrose
Description: One ml 24% sucrose will be given approximately two minutes before the heel stick. Sucrose will be given via oral syringe along with a pacifier.
Study NCT01800318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham NESAP
Description: Four electrodes will be placed on the infant's lower leg, but the TENS unit will not be turned on. The TENS unit will be covered and investigators will not know whether the TENS unit is turned on or not (sham NESAP).
Study NCT01800318 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham NESAP
Description: Four electrodes will be placed on the infant's lower leg, but the TENS unit will not be turned on. The TENS unit will be covered and investigators will not know whether the TENS unit is turned on or not (sham NESAP).
Study NCT01800318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral water
Description: For infants in the control group, 1 ml of water will be given via oral syringe along with a pacifier 2 minutes before the heel stick. Investigators will be blinded on whether the infants are receiving water or oral sucrose.
Study NCT01800318 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Oral water
Description: For infants in the control group, 1 ml of water will be given via oral syringe along with a pacifier 2 minutes before the heel stick. Investigators will be blinded on whether the infants are receiving water or oral sucrose.
Study NCT00893269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramelteon
Description: ramelteon
Study NCT00893269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem
Description: zolpidem
Study NCT04320823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Updated Plasma Collection Feature
Description: Plasma collection using a novel, patented system that supports a more individualized collection approach.
Study NCT04320823 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Current Plasma Collection Approach
Description: Plasma collection using the current collection approach.
Study NCT06319040 — intervention group
Intervention type: OTHER
Intervention: Muscle strength measurement
Description: Muscle strength of both legs, maximal reciprocal concentric isokinetic knee extension (quadriceps) and flexion (hamstring) at 60°/s, 90°/s and 180°/s speeds were evaluated
Study NCT03612843 — intervention group
Intervention type: OTHER
Intervention: Observational dry needle
Description: No intervention provided by the study. Observation of any adverse events that occur surrounding dry needling by a physical therapist.
Study NCT06319040 — intervention group
Intervention type: OTHER
Intervention: Knee joint proprioception
Description: Knee joint proprioception was assessed by joint position sense. Joint position sense was measured by the previously taught ability to actively find joint position (EPAB)
Study NCT06319040 — intervention group
Intervention type: OTHER
Intervention: Balance
Description: The patients and healthy individuals participating in our study were evaluated with the General Stability Index (GSI) for general balance ability, Anterior-Posterior Stability Index (APSI) for anterior-posterior balance ability, Medial-Lateral Stability Index (MLSI) for lateral balance ability and Fall Risk Index (DRI) and Biodex Balance System (Biodex Inc., Shirley, New York, USA) for fall risk. High values obtained indicate deterioration in balance and increased risk of falling.
Study NCT01779505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-4774
Description: GS-4774 is a recombinant yeast-based biological product engineered to express HBV antigens. The product is a heat-killed yeast (S. cerevisiae) containing a chimera of HBV X, Score, and Core antigens.
Study NCT03899584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4-Aminopyridine
Description: Each patient will take 10 mg per kilogram of weight (example: a person weighing 60 kg, will take two capsules three times a day after meals, for a total of 6 capsules / day). Each capsule will contain 10 milligrams of 4-Aminopyridine that will allow to be administered sequentially at progressively higher doses / day. The dose of 4-aminopyridine will increase 10 mg / 2 to 4 weeks.
Study NCT03899584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The placebo arm will include a placebo of microcrystalline cellulose.
Study NCT00754091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymer based lubricating liquid
Description: three sprays of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
Study NCT03562416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib (BIBF 1120, Ofev)
Study NCT03562416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo
Study NCT00840060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AMALS
Description: Addressing multiple aspects of language simultaneously
Study NCT00840060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DTA
Description: Discrete Trial Approach
Study NCT00106574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv every 4 weeks
Study NCT00106574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv every 4 weeks
Study NCT02406729 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue 1,2,3,4 (attenuated) vaccine
Description: Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
Study NCT02406729 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Route:subcutaneous
Study NCT03143998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5172A
Description: A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
Study NCT00784485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xolair injections
Description: In addition to Advair Diskus 250/50 or 500/50, subjects will receive 150 to 375 mg subcutaneous injection every 2 or 4 weeks (depending on IgE levels) for 16 weeks.
Study NCT00556179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoserum (Dermacyd Femina®)
Description: Once a day during three months
Study NCT02046694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: At week 1, patients will begin allopurinol daily (100 mg for weight >30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks).
Study NCT00340379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Target dosage 120-160mg/day based on tolerance
Study NCT00340379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Target dosage 150-200mg/day based on tolerance.
Study NCT00340379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Target dosage 6-8mg/day based on tolerance.
Study NCT06319040 — intervention group
Intervention type: OTHER
Intervention: Fall risk test
Description: Biodex Balance System (Biodex Inc., Shirley, New York, USA) for fall risk
Study NCT00469326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: two days 80mg atorvastatin pre-treatment before PCI
Study NCT00469326 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Atorvastatin
Description: two days 80mg atorvastatin pre-treatment before PCI
Study NCT04265274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: dosing 400mg daily
Study NCT04265274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbin
Description: 25mg/m2 day 1 and 8,
Study NCT04265274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2 day 1
Study NCT04265274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper
Description: 2 mg of elementary Copper daily
Study NCT04631653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VeriSee®
Description: Screening of diabetic retinopathy using a validated deep learning-based software,VeriSee®
Study NCT04113460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga@work program included physical movements, yoga posture, breathing exercise, pranayama and yoga chants. Session with trainer was conducted on worksite once a week for an hour.
Study NCT00700583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination therapy of terazosin and hydrochlorothiazide
Description: 25 mg of hydrochlorothiazide eight hours before bedtime and 4 mg of terazosin at bedtime for 4 weeks
Study NCT04592900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance exercising
Description: selected physical therapy program strengthening the muscles of upper and lower limbs, balancing exercise, gait training in open environment,stretching for elbow flexors and forearms pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors
Study NCT00380419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Description: IPT sessions will address adjustment to pregnancy, concerns about interpersonal relationships, and parenting concerns. Sessions will be weekly, but may be determined by clinical desires of patient and therapist.
Study NCT00869830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biofeedback therapy
Description: biofeedback therapy was applied using the surface electromyography (EMG) method with a perianal sensor (Perry, Elan, SRS Medical Systems, Redmond, WA, USA) and biofeedback PC equipment (Orion, Platinum, SRS Medical Systems, Inc., Redmond, WA, USA).
Study NCT02971241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intergenerational Mobile Technology Opportunities Program
Description: The themes of the 8-week training session are designed based on the objectives of IMTOP: 1) teach skills of tablet use and diabetes self-management behavior tracking app, 2) introduce online community communication to decrease social isolation and obtain social support from family and friends, young volunteers, health care providers, and diabetes peers who have similar condition/interest/ or disease), 3) teach diabetes self-management knowledge and skills based on the evidence-based Chronic Disease Self-Management Program; and 4) teach mobile technology application to healthcare access and daily needs (i.e., online appointment, online refill, appointment reminder, online health information, online training videos, and virtual classes such as e-newspaper, e-books, related sites, apps).
Study NCT02971241 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intergenerational Mobile Technology Opportunities Program
Description: The themes of the 8-week training session are designed based on the objectives of IMTOP: 1) teach skills of tablet use and diabetes self-management behavior tracking app, 2) introduce online community communication to decrease social isolation and obtain social support from family and friends, young volunteers, health care providers, and diabetes peers who have similar condition/interest/ or disease), 3) teach diabetes self-management knowledge and skills based on the evidence-based Chronic Disease Self-Management Program; and 4) teach mobile technology application to healthcare access and daily needs (i.e., online appointment, online refill, appointment reminder, online health information, online training videos, and virtual classes such as e-newspaper, e-books, related sites, apps).
Study NCT00411190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacatib
Description: Subjects will administer 60 or 120 mg tablets in Session 2
Study NCT00411190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen will be administered orally
Study NCT00411190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen will be administered orally
Study NCT00411190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin will be administered orally